

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Gefitinib

INITIATION

Re-assessment required after 4 months

Prerequisites (tick boxes where appropriate)

- ☐ Patient has locally advanced, or metastatic, unresectable, non-squamous Non Small Cell Lung Cancer (NSCLC)
- and
- ☐ Patient is treatment naive
- or
- ☐ Patient has received prior treatment in the adjuvant setting and/or while awaiting EGFR results
- or
- ☐ The patient has discontinued osimertinib or erlotinib due to intolerance
- and
- ☐ The cancer did not progress whilst on osimertinib or erlotinib
- and
- ☐ There is documentation confirming that disease expresses activating mutations of EGFR

CONTINUATION

Re-assessment required after 6 months

Prerequisites (tick box where appropriate)

- ☐ Radiological assessment (preferably including CT scan) indicates NSCLC has not progressed

I confirm that the above details are correct:

Signed: Date: